The Role of Different Cycles of Chemotherapy（Capecitabine-oxaliplatin） in Esophageal Chemoradiotherapy (DCOECRT)
Two Cycles Versus Four Cycles of Capecitabine Combined Oxaliplatin Concurrent Radiotherapy as First-line Therapy for Chinese Locally Advanced Esophageal Squamous Cell Carcinomas, an Open Randomised Phase III Cilinical Trial
Sponsor: Anyang Tumor Hospital
This PHASE3 trial investigates Esophageal Neoplasms and Stage III Esophageal Squamous Cell Carcinoma and is currently ongoing. Anyang Tumor Hospital leads this study, which shows 5 recorded versions since 2014 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
-
Jun 2018 — Jan 2021 [monthly]
Recruiting PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE3
First recorded
Oct 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Anyang Tumor Hospital
- No. 150 Central Hospital of the Chinese People Liberation Army
- The First Affiliated Hospital of Henan University of Science and Technology
- The First Affiliated Hospital of Zhengzhou University
- Xinyang Central Hospital
For direct contact, visit the study record on ClinicalTrials.gov .